세계의 피부 섬유증 치료 시장 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2032년)

Persistence Market Research has recently released a comprehensive report on the global cutaneous fibrosis treatment market. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global cutaneous fibrosis treatment market from 2025 to 2032.

Key Insights:

• Cutaneous Fibrosis Treatment Market Size (2025E): USD 732.0 Million
• Projected Market Value (2032F): USD 1,173.2 Million
• Global Market Growth Rate (CAGR 2025 to 2032): 7.0%

Cutaneous Fibrosis Treatment Market -

Report Scope:

Cutaneous fibrosis is a pathological condition characterized by excessive scarring and tissue hardening due to abnormal wound healing processes. It is commonly associated with conditions such as systemic sclerosis, keloids, and radiation-induced fibrosis. Treatment approaches range from pharmacological interventions, including corticosteroids and antifibrotic agents, to advanced therapies such as laser treatment, stem cell therapy, and regenerative medicine. The market caters to hospitals, dermatology clinics, research institutions, and homecare settings. Market growth is driven by increasing prevalence of fibrotic skin disorders, rising adoption of novel therapeutic approaches, and advancements in regenerative medicine and biologics.

Market Growth Drivers:

The global cutaneous fibrosis treatment market is propelled by several key factors, including rising incidence of conditions such as scleroderma, keloids, and radiation-induced fibrosis. Increasing awareness regarding available treatment options, coupled with growing investments in dermatological research, is contributing to market expansion. Additionally, the introduction of novel biologic therapies, gene-based treatments, and anti-fibrotic drugs is enhancing treatment efficacy and improving patient outcomes. The expanding role of regenerative medicine, including stem cell therapies and platelet-rich plasma (PRP) treatments, is further driving market growth by offering innovative treatment options for fibrotic skin disorders.

Market Restraints:

Despite strong growth prospects, the cutaneous fibrosis treatment market faces challenges, including high treatment costs, limited availability of targeted therapies, and regulatory hurdles associated with the approval of new drugs. The complex pathophysiology of fibrosis makes drug development challenging, leading to extended clinical trial durations and increased R&D expenditures. Additionally, the lack of standardized treatment protocols and limited insurance coverage for advanced therapies pose challenges for market penetration, particularly in emerging economies. Addressing these barriers requires increased research collaboration, improved reimbursement frameworks, and regulatory support for novel treatment modalities.

Market Opportunities:

The cutaneous fibrosis treatment market presents significant growth opportunities driven by advancements in personalized medicine, increasing adoption of combination therapies, and expansion of minimally invasive treatment options. The integration of AI-driven diagnostic tools and predictive modeling in fibrosis treatment is expected to enhance early diagnosis and treatment effectiveness. Furthermore, growing research in anti-fibrotic drug discovery and the development of topical therapies with improved skin penetration offer lucrative market prospects. Strategic partnerships between pharmaceutical companies and research institutes will play a vital role in accelerating innovation and expanding treatment accessibility.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the cutaneous fibrosis treatment market globally?
• Which treatment modalities and drug classes are witnessing the highest adoption in cutaneous fibrosis management?
• How are technological advancements shaping the competitive landscape of the market?
• Who are the key players contributing to the market, and what strategies are they employing to maintain market relevance?
• What are the emerging trends and future prospects in the global cutaneous fibrosis treatment market?

Competitive Intelligence and Business Strategy:

Leading players in the global cutaneous fibrosis treatment market, including Pfizer Inc., Sanofi S.A., and F. Hoffmann-La Roche Ltd., focus on innovation, product differentiation, and strategic collaborations to gain a competitive edge. Companies are investing in R&D to develop novel antifibrotic drugs, biologics, and stem cell-based therapies. Collaborations with academic institutions and biotechnology firms are accelerating drug discovery and clinical trials for emerging treatment options. Additionally, companies are expanding their global presence through strategic mergers, acquisitions, and partnerships to strengthen their product portfolios and enhance market penetration.

Key Companies Profiled:

• Novartis AG
• Pfizer
• Sanofi
• F. Hoffmann-La Roche (Genentech, Inc.)
• Boehringer Ingelheim International GmbH
• Jubilant Cadista
• Horizon Therapeutics USA, Inc.
• Bristol-Myers Squibb Company
• Teva Pharmaceuticals
• Amgen
• Johnson & Johnson Services
• AbbVie
• Bayer
• Merck & Co.
• GlaxoSmithKline
• LEO Pharma
• Actelion Pharmaceuticals

Key Segments Covered in Cutaneous Fibrosis Treatment Industry Research

Cutaneous Fibrosis Treatment Market by Drug Class:

• Corticosteroids
• Anti-fibrotic Drugs
• Immunotherapy
• Immunoglobulins

Cutaneous Fibrosis Treatment Market by Route of Administration:

• Oral
• Injectable
• Topical

Cutaneous Fibrosis Treatment Market by Indication:

• Keloid
• Scleroderma
• Radiation-induced Skin Fibrosis
• Chronic Graft-versus-Host Disease (GvHD)-associated Cutaneous Fibrosis

Cutaneous Fibrosis Treatment Market by Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Online Pharmacies

Region:

• North America
• Latin America
• Europe
• South Asia & Oceania
• East Asia
• Middle East & Africa

Table of Contents

1. Executive Summary

• 1.1. Global Cutaneous Fibrosis Treatment Market Snapshot, 2025 and 2032
• 1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Key Trends
• 2.3. Macro-Economic Factors
  • 2.3.1. Global Sectorial Outlook
  • 2.3.2. Global GDP Growth Outlook
• 2.4. COVID-19 Impact Analysis
• 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

• 3.1. Product Adoption Analysis
• 3.2. Regulatory Landscape
• 3.3. Value Chain Analysis
• 3.4. PESTLE Analysis
• 3.5. Porter's Five Force Analysis

4. Global Cutaneous Fibrosis Treatment Market Outlook

• 4.1. Key Highlights
  • 4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
  • 4.1.2. Absolute $ Opportunity
• 4.2. Market Size (US$ Mn) Analysis and Forecast
  • 4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2024
  • 4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2025-2032
• 4.3. Global Cutaneous Fibrosis Treatment Market Outlook: Drug Class
  • 4.3.1. Introduction / Key Findings
  • 4.3.2. Historical Market Size (US$ Mn) Analysis, By Drug Class, 2019-2024
  • 4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
    • 4.3.3.1. Corticosteroids
    • 4.3.3.2. Anti-fibrotic Drugs
    • 4.3.3.3. Immunotherapy
      • 4.3.3.3.1. Immunoglobulins
      • 4.3.3.3.2. Immunosuppressants
      • 4.3.3.3.3. Janus Kinase (JAK) Inhibitors
      • 4.3.3.3.4. Others
  • 4.3.4. Market Attractiveness Analysis: Drug Class
• 4.4. Global Cutaneous Fibrosis Treatment Market Outlook: Route of Administration
  • 4.4.1. Introduction / Key Findings
  • 4.4.2. Historical Market Size (US$ Mn), By Route of Administration, 2019-2024
  • 4.4.3. Current Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2025-2032
    • 4.4.3.1. Oral
    • 4.4.3.2. Injectable
    • 4.4.3.3. Topical
  • 4.4.4. Market Attractiveness Analysis: Route of Administration
• 4.5. Global Cutaneous Fibrosis Treatment Market Outlook: Indication
  • 4.5.1. Introduction / Key Findings
  • 4.5.2. Historical Market Size (US$ Mn), By Indication, 2019-2024
  • 4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
    • 4.5.3.1. Keloid
    • 4.5.3.2. Scleroderma
    • 4.5.3.3. Radiation-induced Skin Fibrosis
    • 4.5.3.4. Chronic Graft-versus-Host Disease (GvHD)-associated Cutaneous Fibrosis
    • 4.5.3.5. Others
  • 4.5.4. Market Attractiveness Analysis: Indication
• 4.6. Global Cutaneous Fibrosis Treatment Market Outlook: Distribution Channel
  • 4.6.1. Introduction / Key Findings
  • 4.6.2. Historical Market Size (US$ Mn) Analysis, By Distribution Channel, 2019-2024
  • 4.6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
    • 4.6.3.1. Hospital Pharmacies
    • 4.6.3.2. Retail Pharmacies
    • 4.6.3.3. Online Pharmacies
  • 4.6.4. Market Attractiveness Analysis: Distribution Channel

5. Global Cutaneous Fibrosis Treatment Market Outlook: Region

• 5.1. Key Highlights
• 5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2024
• 5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2025-2032
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. East Asia
  • 5.3.4. South Asia & Oceania
  • 5.3.5. Latin America
  • 5.3.6. Middle East & Africa
• 5.4. Market Attractiveness Analysis: Region

6. North America Cutaneous Fibrosis Treatment Market Outlook

• 6.1. Key Highlights
• 6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 6.2.1. By Country
  • 6.2.2. By Drug Class
  • 6.2.3. By Route of Administration
  • 6.2.4. By Indication
  • 6.2.5. By Distribution Channel
• 6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 6.3.1. U.S.
  • 6.3.2. Canada
• 6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
  • 6.4.1. Corticosteroids
  • 6.4.2. Anti-fibrotic Drugs
  • 6.4.3. Immunotherapy
    • 6.4.3.1. Immunoglobulins
    • 6.4.3.2. Immunosuppressants
    • 6.4.3.3. Janus Kinase (JAK) Inhibitors
    • 6.4.3.4. Others
• 6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2025-2032
  • 6.5.1. Oral
  • 6.5.2. Injectable
  • 6.5.3. Topical
• 6.6. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
  • 6.6.1. Keloid
  • 6.6.2. Scleroderma
  • 6.6.3. Radiation-induced Skin Fibrosis
  • 6.6.4. Chronic Graft-versus-Host Disease (GvHD)-associated Cutaneous Fibrosis
  • 6.6.5. Others
• 6.7. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
  • 6.7.1. Hospital Pharmacies
  • 6.7.2. Retail Pharmacies
  • 6.7.3. Online Pharmacies
• 6.8. Market Attractiveness Analysis

7. Europe Cutaneous Fibrosis Treatment Market Outlook

• 7.1. Key Highlights
• 7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 7.2.1. By Country
  • 7.2.2. By Drug Class
  • 7.2.3. By Route of Administration
  • 7.2.4. By Indication
  • 7.2.5. By Distribution Channel
• 7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 7.3.1. Germany
  • 7.3.2. France
  • 7.3.3. U.K.
  • 7.3.4. Italy
  • 7.3.5. Spain
  • 7.3.6. Russia
  • 7.3.7. Turkey
  • 7.3.8. Rest of Europe
• 7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
  • 7.4.1. Corticosteroids
  • 7.4.2. Anti-fibrotic Drugs
  • 7.4.3. Immunotherapy
    • 7.4.3.1. Immunoglobulins
    • 7.4.3.2. Immunosuppressants
    • 7.4.3.3. Janus Kinase (JAK) Inhibitors
    • 7.4.3.4. Others
• 7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2025-2032
  • 7.5.1.1. Oral
  • 7.5.1.2. Injectable
  • 7.5.1.3. Topical
• 7.6. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
  • 7.6.1.1. Keloid
  • 7.6.1.2. Scleroderma
  • 7.6.1.3. Radiation-induced Skin Fibrosis
  • 7.6.1.4. Chronic Graft-versus-Host Disease (GvHD)-associated Cutaneous Fibrosis
  • 7.6.1.5. Others
• 7.7. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
  • 7.7.1.1. Hospital Pharmacies
  • 7.7.1.2. Retail Pharmacies
  • 7.7.1.3. Online Pharmacies
• 7.8. Market Attractiveness Analysis

8. East Asia Cutaneous Fibrosis Treatment Market Outlook

• 8.1. Key Highlights
• 8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 8.2.1. By Country
  • 8.2.2. By Drug Class
  • 8.2.3. By Route of Administration
  • 8.2.4. By Indication
  • 8.2.5. By Distribution Channel
• 8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 8.3.1. China
  • 8.3.2. Japan
  • 8.3.3. South Korea
• 8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
  • 8.4.1. Corticosteroids
  • 8.4.2. Anti-fibrotic Drugs
  • 8.4.3. Immunotherapy
    • 8.4.3.1. Immunoglobulins
    • 8.4.3.2. Immunosuppressants
    • 8.4.3.3. Janus Kinase (JAK) Inhibitors
    • 8.4.3.4. Others
• 8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2025-2032
  • 8.5.1.1. Oral
  • 8.5.1.2. Injectable
  • 8.5.1.3. Topical
• 8.6. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
  • 8.6.1.1. Keloid
  • 8.6.1.2. Scleroderma
  • 8.6.1.3. Radiation-induced Skin Fibrosis
  • 8.6.1.4. Chronic Graft-versus-Host Disease (GvHD)-associated Cutaneous Fibrosis
  • 8.6.1.5. Others
• 8.7. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
  • 8.7.1.1. Hospital Pharmacies
  • 8.7.1.2. Retail Pharmacies
  • 8.7.1.3. Online Pharmacies
• 8.8. Market Attractiveness Analysis

9. South Asia & Oceania Cutaneous Fibrosis Treatment Market Outlook

• 9.1. Key Highlights
• 9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 9.2.1. By Country
  • 9.2.2. By Drug Class
  • 9.2.3. By Route of Administration
  • 9.2.4. By Indication
  • 9.2.5. By Distribution Channel
• 9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 9.3.1. India
  • 9.3.2. Southeast Asia
  • 9.3.3. ANZ
  • 9.3.4. Rest of South Asia & Oceania
• 9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
  • 9.4.1. Corticosteroids
  • 9.4.2. Anti-fibrotic Drugs
  • 9.4.3. Immunotherapy
    • 9.4.3.1. Immunoglobulins
    • 9.4.3.2. Immunosuppressants
    • 9.4.3.3. Janus Kinase (JAK) Inhibitors
    • 9.4.3.4. Others
• 9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2025-2032
  • 9.5.1. Oral
  • 9.5.2. Injectable
  • 9.5.3. Topical
• 9.6. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
  • 9.6.1. Keloid
  • 9.6.2. Scleroderma
  • 9.6.3. Radiation-induced Skin Fibrosis
  • 9.6.4. Chronic Graft-versus-Host Disease (GvHD)-associated Cutaneous Fibrosis
  • 9.6.5. Others
• 9.7. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
  • 9.7.1. Hospital Pharmacies
  • 9.7.2. Retail Pharmacies
  • 9.7.3. Online Pharmacies
• 9.8. Market Attractiveness Analysis

10. Latin America Cutaneous Fibrosis Treatment Market Outlook

• 10.1. Key Highlights
• 10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 10.2.1. By Country
  • 10.2.2. By Drug Class
  • 10.2.3. By Route of Administration
  • 10.2.4. By Indication
  • 10.2.5. By Distribution Channel
• 10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 10.3.1. Brazil
  • 10.3.2. Mexico
  • 10.3.3. Rest of Latin America
• 10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
  • 10.4.1. Corticosteroids
  • 10.4.2. Anti-fibrotic Drugs
  • 10.4.3. Immunotherapy
    • 10.4.3.1. Immunoglobulins
    • 10.4.3.2. Immunosuppressants
    • 10.4.3.3. Janus Kinase (JAK) Inhibitors
    • 10.4.3.4. Others
• 10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2025-2032
  • 10.5.1. Oral
  • 10.5.2. Injectable
  • 10.5.3. Topical
• 10.6. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
  • 10.6.1. Keloid
  • 10.6.2. Scleroderma
  • 10.6.3. Radiation-induced Skin Fibrosis
  • 10.6.4. Chronic Graft-versus-Host Disease (GvHD)-associated Cutaneous Fibrosis
  • 10.6.5. Others
• 10.7. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
  • 10.7.1.
    • 10.7.1.1. Hospital Pharmacies
    • 10.7.1.2. Retail Pharmacies
    • 10.7.1.3. Online Pharmacies
• 10.8. Market Attractiveness Analysis

11. Middle East & Africa Cutaneous Fibrosis Treatment Market Outlook

• 11.1. Key Highlights
• 11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 11.2.1. By Country
  • 11.2.2. By Drug Class
  • 11.2.3. By Route of Administration
  • 11.2.4. By Indication
  • 11.2.5. By Distribution Channel
• 11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 11.3.1. GCC Countries
  • 11.3.2. Egypt
  • 11.3.3. South Africa
  • 11.3.4. Northern Africa
  • 11.3.5. Rest of Middle East & Africa
• 11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
  • 11.4.1. Corticosteroids
  • 11.4.2. Anti-fibrotic Drugs
  • 11.4.3. Immunotherapy
    • 11.4.3.1. Immunoglobulins
    • 11.4.3.2. Immunosuppressants
    • 11.4.3.3. Janus Kinase (JAK) Inhibitors
    • 11.4.3.4. Others
• 11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2025-2032
  • 11.5.1. Oral
  • 11.5.2. Injectable
  • 11.5.3. Topical
• 11.6. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
  • 11.6.1. Keloid
  • 11.6.2. Scleroderma
  • 11.6.3. Radiation-induced Skin Fibrosis
  • 11.6.4. Chronic Graft-versus-Host Disease (GvHD)-associated Cutaneous Fibrosis
  • 11.6.5. Others
• 11.7. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
  • 11.7.1. Hospital Pharmacies
  • 11.7.2. Retail Pharmacies
  • 11.7.3. Online Pharmacies

12. Competition Landscape

• 12.1. Market Share Analysis, 2025
• 12.2. Market Structure
  • 12.2.1. Competition Intensity Mapping By Market
  • 12.2.2. Competition Dashboard
• 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 12.3.1. Novartis AG
    • 12.3.1.1. Overview
    • 12.3.1.2. Segments and Products
    • 12.3.1.3. Key Financials
    • 12.3.1.4. Market Developments
    • 12.3.1.5. Market Strategy
  • 12.3.2. Pfizer
  • 12.3.3. Sanofi
  • 12.3.4. F. Hoffmann-La Roche (Genentech, Inc.)
  • 12.3.5. Boehringer Ingelheim International GmbH
  • 12.3.6. Jubilant Cadista
  • 12.3.7. Horizon Therapeutics USA, Inc.
  • 12.3.8. Bristol-Myers Squibb Company
  • 12.3.9. Teva Pharmaceuticals
  • 12.3.10. Amgen
  • 12.3.11. Johnson & Johnson Services
  • 12.3.12. AbbVie
  • 12.3.13. Bayer
  • 12.3.14. Merck & Co.
  • 12.3.15. GlaxoSmithKline
  • 12.3.16. LEO Pharma
  • 12.3.17. Actelion Pharmaceuticals

13. Appendix

• 13.1. Research Methodology
• 13.2. Research Assumptions
• 13.3. Acronyms and Abbreviations